BioTime, Inc. (NYSEMKT:BTX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Several other equities research analysts have also commented on BTX. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $6.50 price objective (up previously from $6.00) on shares of BioTime in a research report on Monday, June 19th. ValuEngine upgraded BioTime from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, Zacks Investment Research upgraded BioTime from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a research report on Tuesday, July 18th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $5.33.

BioTime (BTX) opened at 2.79 on Friday. The stock has a market cap of $323.09 million, a P/E ratio of 4.69 and a beta of 1.37. BioTime has a 12-month low of $2.47 and a 12-month high of $3.97. The company has a 50 day moving average of $2.79 and a 200-day moving average of $3.03.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/biotime-inc-btx-lowered-to-sell-at-bidaskclub/1611360.html.

In related news, Director Broadwood Partners, L.P. acquired 150,000 shares of the stock in a transaction on Monday, July 31st. The shares were acquired at an average price of $2.80 per share, for a total transaction of $420,000.00. The purchase was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders acquired 173,896 shares of company stock worth $481,220.

Large investors have recently made changes to their positions in the company. Voya Investment Management LLC lifted its position in shares of BioTime by 38.3% during the 2nd quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 8,996 shares in the last quarter. American International Group Inc. lifted its position in shares of BioTime by 8.3% during the 1st quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 3,036 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in shares of BioTime during the 2nd quarter valued at approximately $142,000. Nationwide Fund Advisors lifted its position in shares of BioTime by 2.2% during the 1st quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 939 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its position in shares of BioTime by 25.2% during the 2nd quarter. Moors & Cabot Inc. now owns 49,630 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 10,000 shares in the last quarter.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.